CN1285357A - Snake venom enzyme nerve growth factor - Google Patents

Snake venom enzyme nerve growth factor Download PDF

Info

Publication number
CN1285357A
CN1285357A CN 99111530 CN99111530A CN1285357A CN 1285357 A CN1285357 A CN 1285357A CN 99111530 CN99111530 CN 99111530 CN 99111530 A CN99111530 A CN 99111530A CN 1285357 A CN1285357 A CN 1285357A
Authority
CN
China
Prior art keywords
growth factor
nerve growth
chromatography
acetate buffer
sodium acetate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN 99111530
Other languages
Chinese (zh)
Other versions
CN1133651C (en
Inventor
潘�清
郝文学
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to CNB991115309A priority Critical patent/CN1133651C/en
Publication of CN1285357A publication Critical patent/CN1285357A/en
Application granted granted Critical
Publication of CN1133651C publication Critical patent/CN1133651C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Landscapes

  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The present invention relates to a preparation method of nerve growth factor by using venin. It is characterized by that colbravenom undergoes three-step chromatographic process of CM-sepnadex C50, CM-sphatose FF and Sepndex G75 under the condition of below 10 deg.C to prepare semi-product, to it are added a stabilizing ageng albumin and excipient dextran for freeze-dried product, and It is filtered, filled and freeze-dried so as to obtain the invented product.

Description

Snake venom enzyme nerve growth factor
What the present invention relates to is the processing method for preparing nerve growth factor with snake venom.
Nerve growth factor is a chemical name, Chinese name: neural live plain (the neural factor of giving birth to), and English name: NERVE GROWTH FACTOR, be called for short: NGF.
Nerve growth factor (NGF) is the cell growth regulator of finding the earliest, also is one of most important bioactive molecules of neural system.From finding NGF 40 years so far, brand-new field of neuroscience has been opened up in its discovery and research, has promoted the research and the progress of development biology and cytobiology.For this reason, Nobel judging panels in 1986 have spoken highly of the theory significance and the using value of this work, and should year Nobel Medical Biology award and give two scientist Levi-Montalcini (Italy) and the Cohen (U.S.) that makes outstanding contribution in NGF research.
According to reported literature NGF from many biomaterials separation and purification obtain, these materials comprise: snake venom, mouse submandibular gland, the mature placenta of people, cavy prostate gland and ox seminal vesicle etc., but content the abundantest be still male mice submaxillary gland and multiple snake venom.
Because NGF plays an important role in neural growth and damage, therefore more external drugmakers all drop into a large amount of man power and materials NGF are developed and studies.What foreign study and exploitation were in a leading position at present is Grentech company, and mainly with NGF treatment peripheral nerve injury and some nervus deformability diseases, it is clinical to have entered the second phase at present, but does not form commodity as yet.And the domestic present NGF commodity that are given the ratification that do not have as yet.External like product price of producing is too expensive.It is reported only 0.01mg of NGF that U.S. Sigma company produces, promptly up to 118 dollars, real non-general compatriots can bear.Consider China's snake venom resource than horn of plenty, cheap, if therefrom separate purification NGF very big pharmaceutical use and economic worth will be arranged.
The research of neurotization is the problem that domestic scholars is devoted for years to research always.A large amount of experimental studies results show: nerve growth factor has neuronal development and differentiation such as promoting sympathetic neuron, Sensory neurone and forebrain cholinergic neuron, and keeps their normal function, promotes the reparation after their damages.So it is clinical that nerve growth factor is applied to, remove patient's misery, be to work as forward swing in the previous important problem of our face.Therefore we at first study the nerve growth factor purifying process, and we have set up the technology of a Chinese style scale production nerve growth factor at present, and pharmacology and the clinical application of furtheing investigate nerve growth factor for us lay the foundation.
Purpose of the present invention just provides a kind of processing method for preparing nerve growth factor with snake venom.
The objective of the invention is to take following technical scheme to realize: on the lot of experiments basis, to determine the optimum manufacturing process route of nerve growth factor.From the base-material of the preferred cobra venom of technical parameters such as productive rate, specific activity, through three step chromatographies, the nerve growth factor of the single component of purifying as separation and purification of nerve growth factor.
The nerve growth factor that adopts above-mentioned technical scheme to prepare, animal experiment through preclinical pharmacology shows, nerve growth factor be a kind of to central nervous system and peripheral nervous system growth, grow and the necessary nerve growth active substance of surviving: confirm to have following effects after deliberation: (1) promotes neuronic growth and differentiation.(2) the sophisticated neurone of nutrition is kept its survival and function.(3) have the effector neuron that protection damages, promote the nerve fiber regeneration reparation on this basis.(4) nerve growth factor is the motor neuron chemotropic factor of damaged or generation.
Preparation technology:
All operations is all finished below 10 ℃.
1. CM-Sephadex C50 chromatography
Get cobra venom 10g, be dissolved among 0.01M acid sodium damping fluid, (FH5.8) 100ml, after the dissolving, centrifugal 10000 change, 10 minutes, get supernatant,, change damping fluid 3 times above-mentioned damping fluid 5000ml dialysis, sample is splined on and uses the good chromatography column of 0.01M acetate buffer balance (in 5.5 * 100cm) then, use the 0-0.7MNaCL linear gradient elution, collection has the active protein peak of nerve growth factor, and is concentrated freeze-dried.
2. CM-SpharoseFF chromatography
With above-mentioned spissated sample, be dissolved in the 20ml 0.01M sodium acetate buffer (FH5.8), be splined on and use the good chromatography column of 0.01M sodium acetate buffer (PH5.8) balance (in 2.6 * 50cm), use the 0-1MNaCL linear gradient elution, collection has the active protein peak of nerve growth factor, and is concentrated freeze-dried.
3. SephdexG75 chromatography
With the sample under the above-mentioned CM-SpharoseFF chromatography, be dissolved in 10ml 0.01M sodium acetate buffer, PH5.8 includes among the 0.15MNaCL, and centrifugal 10000 change, get supernatant, last sephdexG75 (2.6 * 100cm) posts (used the 0.01M sodium acetate buffer, PH5.8, it is good to include the 0.15M/L balance), collection contains the active symmetrical peak of NGF, after electrophoresis and high performance liquid chromatography prove simple spike, the dialysis desalination, freeze-drying promptly gets work in-process (about 3mg).
4. preparation prescription:
Raw material: the nerve growth factor work in-process, by the half-finished activity of mensuration of quality standard, every specification 1000 units feed intake by 135%-145%.Add 1% dextran (molecular weight 10,000), and contain the 1.5mg human serum albumin in every medicine, filter packing, freeze-drying makes.
Indication: be used for the treatment of the peripheral nerve injury that a variety of causes causes;
1. peripheral nerve injury due to tension injury, incision, the contusion etc.;
2. metabolic disease: diabetes, uremia etc. cause peripheral neuropathy;
3. protrusion of intervertebral disc, cervical spondylosis causes DPN;
4. the DPN that causes such as antitumor drug taxol, infectious peripheral nerve unit etc.
Usage and consumption and route of administration:
1. each 1000-2000 unit, intramuscular injection, once a day, 20 days is a course of treatment.
2. in the four limbs trauma surgery, can be at administration of art localized pulverization or injured nerve place local injection, each 1-2 props up.
Precaution:
1. this product is the protein preparation, the careful usefulness of allergic constitution.If anaphylaxis occurs, handle by anaphylaxis.
Need vibration repeatedly to dissolve when 2. dissolving medicine.
Validity period and holding conditions:
Preserve tentative 2 years below 10 ℃.

Claims (1)

1, snake venom enzyme nerve growth factor is characterized in that: he has a scientific preparation process:
All operations is all finished below 10 ℃.
1. CM-Sephadex C50 chromatography
Get cobra venom 10g, be dissolved among 0.01M sodium acetate buffer, (FH5.8) 100ml, after the dissolving, centrifugal 10000 change, 10 minutes, get supernatant,, change damping fluid 3 times above-mentioned damping fluid 5000ml dialysis, sample is splined on and uses the good chromatography column of 0.01M acetate buffer balance (in 5.5 * 100cm) then, use the 0-0.7MNaCL linear gradient elution, collection has the active protein peak of nerve growth factor, and is concentrated freeze-dried.
2. CM-SpharoseFF chromatography
With above-mentioned spissated sample; Be dissolved in the 20ml 0.01M sodium acetate buffer (FH5.8), be splined on and use the good chromatography column of 0.01M sodium acetate buffer (PH5.8) balance (in 2.6 * 50cm), use the 0-1MNaCL linear gradient elution, collection has the active protein peak of nerve growth factor, and is concentrated freeze-dried.
3. SephdexG75 chromatography
With the sample under the above-mentioned CM-SpharoseFF chromatography, be dissolved in 10ml 0.01M sodium acetate buffer, PH5.8 includes among the 0.15MNaCL, and centrifugal 10000 change, get supernatant, last sephdexG75 (2.6 * 100cm) posts (used the 0.01M sodium acetate buffer, PH5.8, it is good to include the 0.15M/L balance), collection contains the active symmetrical peak of NGF, after electrophoresis and high performance liquid chromatography prove simple spike, the dialysis desalination, freeze-drying promptly gets work in-process (about 3mg).
4. preparation prescription:
Raw material: the nerve growth factor work in-process, by the half-finished activity of mensuration of quality standard, every specification 1000 units feed intake by 135%-145%.Add 1% dextran (molecular weight 10,000), and contain the 1.5mg human serum albumin in every medicine, filter packing, freeze-drying makes.
CNB991115309A 1999-08-20 1999-08-20 Snake venom enzyme nerve growth factor Expired - Fee Related CN1133651C (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CNB991115309A CN1133651C (en) 1999-08-20 1999-08-20 Snake venom enzyme nerve growth factor

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CNB991115309A CN1133651C (en) 1999-08-20 1999-08-20 Snake venom enzyme nerve growth factor

Publications (2)

Publication Number Publication Date
CN1285357A true CN1285357A (en) 2001-02-28
CN1133651C CN1133651C (en) 2004-01-07

Family

ID=5275142

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB991115309A Expired - Fee Related CN1133651C (en) 1999-08-20 1999-08-20 Snake venom enzyme nerve growth factor

Country Status (1)

Country Link
CN (1) CN1133651C (en)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008020744A2 (en) * 2006-08-16 2008-02-21 Wisdom Asset Company Method for extracting the nerve tissue growth factor from v.lebetina linnaeus venom
CN103159844A (en) * 2011-12-19 2013-06-19 中国科学院生物物理研究所 Method capable of reducing immunotoxicity of venom nerve growth factor and enabling immunotoxicity to be drug alternative of mouse origin nerve growth factor
CN104480064A (en) * 2014-08-01 2015-04-01 广西医科大学 Cobra venom's nerve growth factor-induced chondrogenic differentiation method of stem cells
CN113214379A (en) * 2021-04-07 2021-08-06 云南龙凤谷生物药业有限公司 Preparation method of cobra venom nerve growth factor

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008020744A2 (en) * 2006-08-16 2008-02-21 Wisdom Asset Company Method for extracting the nerve tissue growth factor from v.lebetina linnaeus venom
WO2008020744A3 (en) * 2006-08-16 2008-07-10 Wisdom Asset Company Method for extracting the nerve tissue growth factor from v.lebetina linnaeus venom
CN103159844A (en) * 2011-12-19 2013-06-19 中国科学院生物物理研究所 Method capable of reducing immunotoxicity of venom nerve growth factor and enabling immunotoxicity to be drug alternative of mouse origin nerve growth factor
CN103159844B (en) * 2011-12-19 2015-01-07 中国科学院生物物理研究所 Method capable of reducing immunotoxicity of venom nerve growth factor and enabling immunotoxicity to be drug alternative of mouse origin nerve growth factor
CN104480064A (en) * 2014-08-01 2015-04-01 广西医科大学 Cobra venom's nerve growth factor-induced chondrogenic differentiation method of stem cells
CN113214379A (en) * 2021-04-07 2021-08-06 云南龙凤谷生物药业有限公司 Preparation method of cobra venom nerve growth factor

Also Published As

Publication number Publication date
CN1133651C (en) 2004-01-07

Similar Documents

Publication Publication Date Title
CN102327292A (en) Refined powder of sheep embryo and sheep placenta and preparation method thereof
CN1133651C (en) Snake venom enzyme nerve growth factor
CN102327290B (en) Refined sheep placenta extract prepared from sheep embryo and sheep placental peptide and preparation method
EP0367840B1 (en) Process for producing by chromatography a non-infectious antihemophilic factor with high purity
EP0554887A1 (en) The use of mammalian liver extract for the manufacture of a medicament to treat presenile or senile dementia
EP1597271A2 (en) Peptides directed against antibodies, which cause cold-intolerance, and the use thereof
EP1326893A2 (en) Plasma fraction containing bikunin, method for the production thereof and use of the same
CN102327291A (en) Stock solution of sheep embryo and sheep placental peptide and preparation method thereof
CN1341662A (en) Scorpion pain-stopping anti-tumor Val-Arg-Gly peptide and its preparation method
CN103463618B (en) Application of recombinant ganoderma lucidum immunoregulatory protein in preparing drug for treating focal cerebral ischemia
CN114681498A (en) A herba Sabinae chinensis total flavone extract with neuroprotective activity, and its preparation method and application
US5151498A (en) Glycoprotein from avena sativa, process for its preparation, and pharmaceutical compositions containing same
CN1042493C (en) Process for preparation of human placental thymosin
CN1051456C (en) Process for preparing nerve growth factor
DK171419B1 (en) Microbially Prepared Human Interleukin-1, Methods of Preparation thereof, and Pharmaceutical Preparations Containing It, and Its Use in Treatment and Prophylaxis
JPH02282333A (en) Fibrous cyanobacteria extract
EP0889053B1 (en) BK-RiV preparations for teatment of proliferative cellular disorders
CN105315359A (en) Deletion type recombinant human mesencephalic astrocyte-derived neurotrophic factor
CN1470528A (en) Snake venom enzyme nerve growth factor for treating diabetic concurrent peripheral nervous pathological complication
US5324524A (en) Yeast derived mitogen
RU2799637C1 (en) Method of producing biologically active peptide-amino acid preparation based on human blood plasma
CN1042833C (en) Process for preparing growth factor of human nerve by embryonic down or decidual
CN1634139A (en) Injectio of brain protein hydrolysate and its preparing process
RU2244928C2 (en) Endogenic pharmaceutical composition prepared on basis of goal-seeking activation of humoral mediators of brain cortex nerve ending
CN118105463A (en) Application of fat decellularized active protein in resisting Alzheimer's disease

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C57 Notification of unclear or unknown address
DD01 Delivery of document by public notice

Addressee: Hao Wenxue

Document name: Notice of publication of application for patent for invention

C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C19 Lapse of patent right due to non-payment of the annual fee
CF01 Termination of patent right due to non-payment of annual fee